Skip to main content

Medical Oncology

Ausgabe 10/2023

Inhalt (29 Artikel)

Open Access Original Paper

Metformin as a promising target for DPP4 expression: computational modeling and experimental validation

Amr Ahmed El-Arabey, Haiyan Zhang, Mohnad Abdalla, Samia T. Al-Shouli, Samia S. Alkhalil, Yi Liu

Original Paper

Chrysin and chrysin-loaded nanocarriers induced immunogenic cell death on B16 melanoma cells

Yasaman Oliyapour, Sheida Dabiri, Ommoleila Molavi, Mohammad Saeid Hejazi, Soodabeh Davaran, Sevda Jafari, Soheila Montazersaheb

Original Paper

In vitro siRNA-mediated GPX4 and AKT1 silencing in oxaliplatin resistance cancer cells induces ferroptosis and apoptosis

Morteza Golbashirzadeh, Hamid Reza Heidari, Ali Asghar Aghamolayi, Yasin Fattahi, Mehdi Talebi, Ahmad Yari Khosroushahi

Original Paper

EZH2 inhibitor Tazemetostat synergizes with JQ-1 in esophageal cancer by inhibiting c-Myc signaling pathway

Nan Ding, Abin You, Senxia Zhao, Hu Yang, Chunping Lai, Feng Ye

Open Access Original Paper

Targeting MerTK decreases efferocytosis and increases anti-tumor immune infiltrate in prostate cancer

Kayla V. Myers Chen, Amber E. de Groot, Sabrina A. Mendez, Mikaela M. Mallin, Sarah R. Amend, Kenneth J. Pienta

Original Paper

Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment

Hongyu Zhang, Hao Huang, Shaoxian Wu, Xian He, Junjun Chen, Xiao Zheng, Lujun Chen, Zhigang Wang

Open Access Original Paper

The NEDD8-activating enzyme E1 UBA3 orchestrates the immunosuppressive microenvironment in lung adenocarcinoma via the NF-кB pathway

Xiongzhi Lin, Shuhan Yang, Caichuan Zhou, Chengcheng Ao, Dongsheng Sun

Original Paper

Knockdown of SIX4 inhibits pancreatic cancer cells via apoptosis induction

Mohammad Heiat, Ehsan Rezaei, Javad Gharechahi, Masoumeh Abbasi, Javad Behroozi, Mohammad Ali Abyazi, Behzad Baradaran

Original Paper

RIG-I promotes cell proliferation in esophageal squamous cell carcinoma by facilitating p21 degradation

Meng Wang, Yangyang Zhang, Liping Gao, Hailin Zhang, Zhenwei Yang, Jialong Liu, Wenqing Shan, Lingxiu Zeng, Ranran Zhang, Yong Li, Jing Liu

Original Paper

The apoptotic effect of the Lycopodium clavatum extracts on MCF-7 human breast cancer cells

Yusuf Kucukbagriacik, Mohammadreza Dastouri, Humeyra Yilmaz, Evrim Gunes Altuntas

Original Paper

GLDC promotes colorectal cancer metastasis through epithelial–mesenchymal transition mediated by Hippo signaling pathway

Hao Yu, Xueqing Hu, Yingru Zhang, Jiajia Wang, Zhongya Ni, Yan Wang, Huirong Zhu

Open Access Original Paper

Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mTOR pathway

IlJin Sim, WonGyom Choe, JinJu Ri, Hang Su, Safwat Adel Abdo Moqbel, WeiQi Yan

Original Paper

AKT-independent signaling in PIK3CA-mutant thyroid cancer mediates resistance to dual SRC and MEK1/2 inhibition

Madison M. Rose, Kelsey W. Nassar, Vibha Sharma, Rebecca E. Schweppe

Original Paper

Effect of insulin on IR and GLP1-R expressions in HT22 cells

Melek Tunc-Ata, Zeynep Mine Altunay, Aysel Alphan, Vural Kucukatay

Original Paper

Expanding CYLD protein in NF-κβ/TNF-α signaling pathway in response to Lactobacillus acidophilus in non-metastatic rectal cancer patients

Farhad Zamani, Solmaz Khalighfard, Mohammad Reza Kalhori, Amirhoushang Poorkhani, Taghi Amiriani, Payam Hosseinzadeh, Ebrahim Esmati, Mahdi Alemrajabi, Alireza Nikoofar, Fahimeh Safarnezhad Tameshkel, Ali Mohammad Alizadeh

Original Paper

RETRACTED ARTICLE: Silencing POLE2 promotes apoptosis and inhibits proliferation of oral squamous cell carcinomas by inhibiting PI3K/AKT signaling pathway

Shengyou Ge, Kexin Wang, Yuxiang Meng, Zongxuan He, Xiaochen Yang, Wei Shang, Lin Wang

Original Paper

Single-cell transcriptomic analysis reveals crucial oncogenic signatures and its associative cell types involved in gastric cancer

Karthik Sekaran, Rinku Polachirakkal Varghese, Hatem Zayed, Achraf El Allali, C. George Priya Doss

Review Article

Role of plectin and its interacting molecules in cancer

Keyu Gao, Zhimin Gao, Mingyi Xia, Hailong Li, Jiehui Di

Review Article

Novel insights on perils and promises of miRNA in understanding colon cancer metastasis and progression

Lubna Tariq, Azher Arafah, Nouroz Sehar, Aarif Ali, Andleeb Khan, Iyman Rasool, Shahzada Mudasir Rashid, Sheikh Bilal Ahmad, Saba Beigh, Tanveer Ul Hassan Dar, Muneeb U. Rehman

Review Article

Therapeutic approaches for HTLV-1-associated adult T-cell leukemia/lymphoma: a comprehensive review

Arash Letafati, Roben Soheili, Mehdi Norouzi, Parastoo Soleimani, Sayed-Hamidreza Mozhgani

Review Article

Role of tissue markers associated with tumor microenvironment in the progression and immune suppression of oral squamous cell carcinoma

Suganya Ramalingam, Sivaramakrishnan Shantha, Susruthan Muralitharan, Uma Sudhakar, Harikrishnan Thamizhchelvan, Venkatachalam Deepa Parvathi

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.